Research programme: cancer vaccine - Cantech

Drug Profile

Research programme: cancer vaccine - Cantech

Alternative Names: Immune-therapeutic protein; ITP

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Canteck Pharma
  • Developer Cantech Holding
  • Class Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Cancer
  • Research Autoimmune disorders

Most Recent Events

  • 07 Jun 2016 Registered for Cancer in Mexico (unspecified route) before June 2016
  • 27 May 2016 Reve Technologies is now called Cantech Holding
  • 10 May 2016 Early research in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top